secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039049
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 core lung diagnostics revenue up 58% YoY to $11.4M; raises $27.5M
-----------------------------------------------------------------------------

- Core lung diagnostic revenue $11.4M (+58% YoY, +33% QoQ); gross margin 73% vs 64% in Q2 2022.
- Net loss $13.4M improved 16% YoY; cash burn reduced 56% QoQ to $7.9M.
- Raised $27.5M in private placement post-quarter from largest shareholders, board, and management.
- Reaffirmed FY2023 total revenue guidance of $52-55M.
- Achieved primary endpoint of ORACLE study: 74% reduction in unnecessary procedures using Nodify XL2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/0000950170-23-039049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023039049/bdsx-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer